Cambridge Isotope Laboratories, Inc. (CIL) is the world’s leading producer of stable isotopes and stable isotope-labeled compounds. With over 400 employees and laboratories in four countries, CIL specializes in the process of labeling biochemical and organic compounds with highly enriched, stable (nonradioactive) isotopes of carbon, hydrogen, nitrogen and oxygen. Our chemists substitute common atoms (e.g., ¹H, ¹²C, ¹⁴N, ¹⁶O) with rare, highly valued isotopes (e.g., ²H or D, ¹³C, ¹⁵N, ¹⁸O) so that the final product can be readily measured or traced using mass spectrometry (MS) or nuclear magnetic resonance (NMR). CIL’s products are utilized in laboratories, medical, government and academic research centers and health care facilities worldwide. We are proud that CIL products have contributed to medical advancements in cancer research, new-drug development, environmental analysis, genomics and proteomics, and medical diagnostic research. In the past decade, as the fields of proteomics and metabolomics have developed as leading techniques for determining biomarkers for disease presence, progression and the monitoring of therapeutic response, CIL has worked closely with industry leaders and researchers to provide the stable isotope-labeled tools needed for improved quantitation of complex systems.

CIL`s vision began when it was founded in 1981 by Dr. Joel Bradley, an organic chemist from MIT. Drawing on a commitment to high-quality products, superior customer service, innovative new products and breadth of product lines, CIL quickly emerged as a leader in its field. CIL now produces more than 15,000 products and has ISO 13485, ISO/IEC 17025 and ISO Guide 34 quality systems, as well as cGMP production capabilities. Over the past several decades CIL has increased its global footprint and now has over 400 employees in its facilities located in four countries. The CIL group is comprised of five companies: Cambridge Isotope Laboratories, Inc. (CIL) and CIL Isotope Separations, LLC (CIS) in the US; CIL Canada in Montreal, Canada; Euriso-Top in Saclay, France; and ABX GmbH in Dresden, Germany.

CIL’s state-of-the-art production facilities are located at the company’s headquarters in Tewksbury, Massachusetts, and the company’s primary production laboratories are located in Andover, Massachusetts. Our isotope-separation facility located in Xenia, Ohio, houses the world’s largest ¹³C and ¹⁸O isotope-separation facilities and the world’s only commercial D₂O enrichment columns.

Dr. Bradley and the CIL Executive Team all share the same commitment to quality and service. Our experts collaborate with all of our customers to aid in pivotal research that is being conducted in laboratories worldwide. Our partnerships not only help to support our global reach but allow us to bring forward innovative products in our pursuit of scientific discovery.

Chenodeoxycholic Acid (2,2,4,4-D4, 98%) 100 UG/ML in Methanol